Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS ) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis .

The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy.

These doses were selected based on the company’s prior experience evaluating soquelitinib in T-cell lymphoma patients.

The company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 who received soquelitinib 100 mg oral twice per day and four who received placebo), with follow-up at 28 days and 58 days.

The mean baseline EASI and IGA scores for soquelitinib patients were 20.4 and 3.0, respectively, compared to 18.5 and 3.3 for placebo patients.

EASI scores at 28-day and 58-day follow-up demonstrate a favorable effect of soquelitinib treatment compared to placebo.

The soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soquelitinib group was seen with mean EASI reduction of 69.1% (n=10) compared to mean EASI reduction of 19.1% for the placebo group.

No significant safety issues were observed. All the patients completed 28 days of dosing. One patient reported Grade 1 nausea that did not interfere with the subject receiving the full treatment course, and one patient developed COVID-19 on day 28 of treatment; that patient had an uneventful recovery.

Price Action: CRVS stock is down 36.80% at $4.67 at the last check on Wednesday.

Read Next:

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.